Lymphoma & Plasma Cell Disorders
News
CPI-613 receives orphan designation for BL
The US Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613 for the treatment of Burkitt lymphoma (BL). CPI-613 is a...
News
Many CCSs not concerned about future health
A survey of more than 15,000 childhood cancer survivors (CCSs) revealed that many were unconcerned about their risk of health problems. Thirty-...
Conference Coverage
CAR T in DLBCL: Liso-cel has ‘remarkable’ efficacy in cohort
CHICAGO – Could liso-cel be the next CAR T-cell therapy to compete in DLBCL?
News
Combo treatment under review for Waldenstrom macroglobulinemia
The FDA has granted priority review to the combination of ibrutinib plus rituximab.
News
Ibrutinib sNDA receives priority review
The US Food and Drug Administration (FDA) has accepted for priority review a supplemental new drug application (sNDA) for ibrutinib (Imbruvica®)...
Conference Coverage
T-cell therapy induced CMRs with no CRS
CHICAGO—A novel CD19-targeted T-cell therapy induced complete metabolic responses (CMRs) and no cytokine release syndrome (CRS) in patients with B...
Feature
CAR T-cell approvals: multiple myeloma likely next up
Conference Coverage
Inhibitor exhibits activity in B- and T-cell NHLs
STOCKHOLM—The dual SYK/JAK inhibitor cerdulatinib has demonstrated efficacy in a phase 2 trial of patients with heavily pretreated B- and T-cell...
Conference Coverage
Is CLL chemoimmunotherapy dead? Not yet
CHICAGO – Frontline use of chemoimmunotherapy is complicated.
Conference Coverage
Combo proves ‘beneficial’ for ‘unfit’ CLL patients
STOCKHOLM—Obinutuzumab plus chlorambucil (G-Clb) is a “valid and beneficial” frontline treatment option for “unfit” patients with chronic...
News
FDA places SB-generated CAR T-cell therapy on clinical hold
The US Food and Drug Administrated (FDA) placed a clinical hold on the phase 1 trial of the Sleeping Beauty (SB)-generated CAR T-cell therapy in...